Exelixis Accounts Receivables 2011-2026 | EXEL

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Exelixis

2026	2025	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
287 M	265 M	237 M	215 M	283 M	119 M	-	163 M	77.3 M	42.2 M	5.18 M	4.88 M	3.94 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
287 M	3.94 M	142 M

Quarterly Accounts Receivables Exelixis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
310 M	292 M	282 M	265 M	270 M	397 M	241 M	237 M	248 M	233 M	234 M	215 M	215 M	235 M	191 M	283 M	179 M	172 M	178 M	119 M	166 M	121 M	137 M	-	170 M	97.5 M	108 M	163 M	163 M	163 M	163 M	11.6 M	88.9 M	81.2 M	81.2 M	40.4 M	91.2 M	40.4 M	40.4 M	5.18 M	5.18 M	5.18 M	5.18 M	4.88 M	4.88 M	4.88 M	4.88 M	3.94 M	3.94 M	3.94 M	3.94 M	2.75 M	2.75 M	2.75 M	2.75 M	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
397 M	2.75 M	126 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Amarin Corporation plc AMRN	134 M	$ 15.0	-0.13 %	$ 6.11 B	Irlanda
Adverum Biotechnologies ADVM	886 K	-	-	$ 86.2 M	USA
Acasti Pharma ACST	802 K	-	4.01 %	$ 150 M	Canada
I-Mab IMAB	130 M	-	-	$ 866 M	China
Aptorum Group Limited APM	62.2 K	$ 0.82	-2.71 %	$ 4.47 M	China
Adagene ADAG	3 M	$ 2.99	0.17 %	$ 168 M	China
Acorda Therapeutics ACOR	17.3 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	3.27 M	-	-0.23 %	$ 916 M	USA
Brickell Biotech BBI	1.13 M	-	-5.38 %	$ 6.06 M	USA
Aptinyx APTX	257 K	-	-39.0 %	$ 4.57 M	USA
Arena Pharmaceuticals ARNA	1.65 M	-	-6.81 %	$ 3.04 B	USA
BeiGene, Ltd. BGNE	676 M	-	0.49 %	$ 251 B	Cayman-islands
Aridis Pharmaceuticals ARDS	1 M	-	17.91 %	$ 11.1 M	USA
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
Athersys ATHX	739 K	-	3.77 %	$ 22.4 M	USA
Baudax Bio BXRX	335 K	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	1.54 M	-	-10.95 %	$ 876 K	USA
Autolus Therapeutics plc AUTL	109 K	$ 1.41	-1.4 %	$ 360 M	Britain
Amneal Pharmaceuticals AMRX	639 M	$ 14.74	-0.14 %	$ 4.55 B	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
Alpine Immune Sciences ALPN	392 K	-	-	$ 2.17 B	USA